Drug Profile
Cabotegravir/rilpivirine - Johnson & Johnson Innovative Medicine/ViiV Healthcare
Alternative Names: CAB LA + RPV LA combination therapy; CABENUVA; Cabotegravir and rilpivirine extended release injectable suspensions; Cabotegravir plus rilpivirine combination therapy; GSK 1265744 plus rilpivirine combination therapy; GSK 1265744 plus TMC 278 combination therapy; Long-acting cabotegravir plus long-acting rilpivirine combination therapyLatest Information Update: 12 Mar 2024
Price :
$50
*
At a glance
- Originator Janssen Pharmaceuticals; ViiV Healthcare
- Developer GSK; Johnson & Johnson Innovative Medicine; National Institute of Allergy and Infectious Diseases; ViiV Healthcare
- Class Antiretrovirals; Benzonitrile; Fluorobenzenes; Nitriles; Oxazoles; Pyrazines; Pyridones; Pyrimidines; Small molecules
- Mechanism of Action HIV integrase inhibitors; Non-nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed HIV-1 infections
Most Recent Events
- 06 Mar 2024 Efficacy and adverse events data from the phase III LATITUDE trial in HIV-1 infections were released by ViiV Healthcare
- 11 Oct 2023 Updated efficacy and adverse event data from a phase III SOLAR trial in HIV Infections presented at the IDWeek (IDW-2023)
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)